167 related articles for article (PubMed ID: 31582907)
1. Selecting short length nucleic acids localized in exosomes improves plasma
Kim Y; Shin S; Kim B; Lee KA
Cancer Cell Int; 2019; 19():251. PubMed ID: 31582907
[TBL] [Abstract][Full Text] [Related]
2. Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy.
Kim Y; Shin S; Lee KA
Cancer Cell Int; 2021 Jan; 21(1):50. PubMed ID: 33435996
[TBL] [Abstract][Full Text] [Related]
3. Exosome-Based Detection of
Castellanos-Rizaldos E; Grimm DG; Tadigotla V; Hurley J; Healy J; Neal PL; Sher M; Venkatesan R; Karlovich C; Raponi M; Krug A; Noerholm M; Tannous J; Tannous BA; Raez LE; Skog JK
Clin Cancer Res; 2018 Jun; 24(12):2944-2950. PubMed ID: 29535126
[No Abstract] [Full Text] [Related]
4. [Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis].
Su F; Zheng K; Fu Y; Wu Q; Tang Y; Wang W; Jiang L
Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):389-396. PubMed ID: 29764589
[TBL] [Abstract][Full Text] [Related]
5. Application of CRISPR/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer.
Kim B; Kim Y; Shin S; Lee ST; Cho JY; Lee KA
Cancer Cell Int; 2022 Feb; 22(1):82. PubMed ID: 35168603
[TBL] [Abstract][Full Text] [Related]
6. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.
Möhrmann L; Huang HJ; Hong DS; Tsimberidou AM; Fu S; Piha-Paul SA; Subbiah V; Karp DD; Naing A; Krug A; Enderle D; Priewasser T; Noerholm M; Eitan E; Coticchia C; Stoll G; Jordan LM; Eng C; Kopetz ES; Skog J; Meric-Bernstam F; Janku F
Clin Cancer Res; 2018 Jan; 24(1):181-188. PubMed ID: 29051321
[No Abstract] [Full Text] [Related]
7. Detection and quantification of
Silveira C; Sousa AC; Janeiro A; Malveiro S; Teixeira E; Brysch E; Pantarotto M; Felizardo M; Madureira R; Nogueira F; Guimarães C; Matos C; Canário D; Bruges-Armas J; Carmo-Fonseca M
Transl Lung Cancer Res; 2021 Mar; 10(3):1200-1208. PubMed ID: 33889502
[TBL] [Abstract][Full Text] [Related]
8. Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system.
Suzawa K; Yamamoto H; Ohashi K; Hashida S; Tomida S; Kubo T; Maki Y; Soh J; Tsukuda K; Kiura K; Miyoshi S; Toyooka S
Oncol Rep; 2017 May; 37(5):3100-3106. PubMed ID: 28405680
[TBL] [Abstract][Full Text] [Related]
9. Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients.
Yu Q; Huang F; Zhang M; Ji H; Wu S; Zhao Y; Zhang C; Wu J; Wang B; Pan B; Zhang X; Guo W
Mol Med Rep; 2017 Aug; 16(2):1157-1166. PubMed ID: 29067441
[TBL] [Abstract][Full Text] [Related]
10. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
[TBL] [Abstract][Full Text] [Related]
12. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
13. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy.
Li YS; Jiang BY; Yang JJ; Zhang XC; Zhang Z; Ye JY; Zhong WZ; Tu HY; Chen HJ; Wang Z; Xu CR; Wang BC; Du HJ; Chuai S; Han-Zhang H; Su J; Zhou Q; Yang XN; Guo WB; Yan HH; Liu YH; Yan LX; Huang B; Zheng MM; Wu YL
Ann Oncol; 2018 Apr; 29(4):945-952. PubMed ID: 29346604
[TBL] [Abstract][Full Text] [Related]
14. Development, validation, and comparison of gene analysis methods for detecting
Hanibuchi M; Kanoh A; Kuramoto T; Saito T; Tobiume M; Saijo A; Kozai H; Kondo M; Morizumi S; Yoneda H; Kagawa K; Ogino H; Sato S; Kawano H; Otsuka K; Toyoda Y; Nokihara H; Goto H; Nishioka Y
Oncotarget; 2019 Jun; 10(38):3654-3666. PubMed ID: 31217900
[TBL] [Abstract][Full Text] [Related]
15. Exosome-based detection of activating and resistance
Castellanos-Rizaldos E; Zhang X; Tadigotla VR; Grimm DG; Karlovich C; Raez LE; Skog JK
Oncotarget; 2019 Apr; 10(30):2911-2920. PubMed ID: 31080561
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice.
González de Aledo-Castillo JM; Arcocha A; Victoria I; Martinez-Puchol AI; Sánchez C; Jares P; Rodríguez GF; Viñolas N; Reyes R; Reguart N; Puig-Butillé JA
J Thorac Dis; 2021 Mar; 13(3):1658-1670. PubMed ID: 33841957
[TBL] [Abstract][Full Text] [Related]
17. Selective gene amplification to detect the T790M mutation in plasma from patients with advanced non-small cell lung cancer (NSCLC) who have developed epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance.
Nishikawa S; Kimura H; Koba H; Yoneda T; Watanabe S; Sakai T; Hara J; Sone T; Kasahara K; Nakao S
J Thorac Dis; 2018 Mar; 10(3):1431-1439. PubMed ID: 29707292
[TBL] [Abstract][Full Text] [Related]
18. Sputum cell-free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR-TKIs.
Wang Z; Li X; Zhang L; Xu Y; Wang M; Liang L; Jiao P; Li Y; He S; Du J; He L; Tang M; Sun M; Yang L; Di J; Zhu G; Li L; Liu D
Cancer Med; 2021 May; 10(10):3323-3331. PubMed ID: 33932095
[TBL] [Abstract][Full Text] [Related]
19. Association of mutant EGFR L858R and exon 19 concentration in circulating cell-free DNA using droplet digital PCR with response to EGFR-TKIs in NSCLC.
Zhu YJ; Zhang HB; Liu YH; Zhu YZ; Chen J; Li Y; Bai JP; Liu LR; Qu YC; Qu X; Chen X; Zheng GJ
Oncol Lett; 2017 Aug; 14(2):2573-2579. PubMed ID: 28789464
[TBL] [Abstract][Full Text] [Related]
20. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
